School of Health Sciences, Swinburne University of Technology, Melbourne, Australia.
3 papers in the library · 15 citations · publishing 2025
General Hospital Psychiatry August 12, 2025 Margaret Ross, Ravi Iyer, M.l. Williams et al. 13 citations
Psilocybin-assisted psychotherapy appears safe and may provide lasting relief from depression and anxiety for people facing a life-threatening illness.
Therapeutic Advances in Psychopharmacology September 1, 2025 Sally Meikle, Olivia Carter, Paul Liknaitzky et al. 2 citations
In an open-label pilot trial, two 25 mg doses of psilocybin combined with psychotherapy produced a clinically meaningful reduction in depressive symptoms at 3 weeks in people with treatment-resistant depression. The average improvement was sustained at 20 weeks, but individual responses varied: two participants showed lasting benefit, three relapsed, and two did not improve. Mindset before dosing, spiritual experiences, and perceptual changes during the session predicted treatment trajectory, whereas treatment expectations did not. No serious adverse events occurred. The findings support further research into tailoring psilocybin therapy to individual variability.
The International Journal of Neuropsychopharmacology August 1, 2025 Susan Meikle, Olivia Carter, Paul Liknaitzky et al.
A small pilot trial of psilocybin with psychotherapy for treatment-resistant depression found a clinically meaningful reduction in depressive symptoms three weeks after the second dose, with an average improvement of 7.14 points on the depression scale and a large effect size. However, individual responses varied widely: two participants showed lasting improvement, three relapsed, and two saw no substantial benefit. Mindset before dosing and spiritual or perceptual experiences during the session predicted treatment trajectory, but prior expectations did not. The study supports further research into tailoring psychedelic therapy to individual differences.